ReviewBioscience of microbiota, food and health2026
Gut microbiota: a potential therapeutic target for hyperuricemia and gout.
Review in Bioscience of microbiota, food and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of hyperuricemia (HUA) and gout has increased in recent decades. Current therapeutic approaches for HUA/gout are often limited by potential risks, necessitating the exploration of safer and more effective treatment options. Emerging evidence highlights the gut microbiota as a pivotal regulator of uric acid (UA) homeostasis. This review synthesizes current advances in microbiota-targeted interventions for HUA/gout, focusing on mechanistic insights and translational potential. We aim to provide a roadmap for optimizing microbiota-based therapies in HUA/gout management by bridging mechanistic discoveries with clinical translation. Gut microbiota can mitigate HUA/gout through several mechanisms, including regulating UA and purine metabolism, alleviating inflammation and modulating immune response, and enhancing the integrity of the intestinal barrier. Therapeutic strategies targeting gut microbiota include probiotics, prebiotics, traditional Chinese medicine, and fecal microbiota transplantation, which offer multi-target and multi-pathway benefits. While these microbiota-targeted therapies offer advantages over conventional drugs, several challenges remain. Future research should prioritize mechanistic elucidation, personalized microbiota modulation, and large-scale trials to optimize therapeutic paradigms for HUA/gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.